The primary end point of overall response rate has been met in the COMPANION-002 trial of tovecimig and paclitaxel in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback